Thrombolytics

Mechanism

The body has a built-in cleanup system for clots called fibrinolysis. Plasminogen is an inactive protein woven into every clot; the body slowly converts a little of it to plasmin, which slices through fibrin strands and breaks the clot into soluble fragments (D-dimer is one). Thrombolytic drugs accelerate this same conversion, so a clot that took hours to form can be digested within a short infusion. This is the defining conceptual difference from every other class in this topic: heparin, warfarin, and the direct oral anticoagulants prevent the cascade from extending fibrin, and antiplatelets prevent platelets from aggregating — but neither touches fibrin already cross-linked into a clot. Only a thrombolytic tears down existing thrombus.

The agents

Alteplase (tPA) is a recombinant version of the body's own enzyme and remains a reference agent for acute ischemic stroke. Tenecteplase is an engineered tPA variant with a longer half-life and stronger fibrin selectivity, allowing single-bolus dosing, and is increasingly favored for simpler administration. Reteplase is another engineered tPA variant given as spaced boluses. All three are "fibrin-specific," preferentially activating plasminogen already bound to fibrin. Streptokinase, derived from streptococcal bacteria, was the original thrombolytic and works indirectly by complexing with plasminogen to activate more plasminogen. Being bacterial and foreign to the body, it is antigenic: patients can form antibodies against it, and prior exposure can blunt its effect or trigger allergic reactions. It has been largely retired in favor of fibrin-specific agents where available, but remains cheaper in resource-limited settings.

Indications and the time-is-tissue principle

Acute ischemic stroke is a headline indication: a clot blocking a cerebral artery starves brain tissue, and thrombolytic therapy can restore flow before it dies — but only within a defined eligibility window from symptom onset. Every increment of delay shrinks the salvageable brain volume and raises the risk that dissolving the clot causes bleeding into already-dead tissue instead, so "time is brain" governs the stroke pathway.

STEMI is treated first-line with percutaneous coronary intervention (PCI). Thrombolytics are the fallback when timely PCI is unavailable — far from a catheterization lab, for example — because an untreated occlusion keeps killing heart muscle, and earlier administration means more myocardial salvage. Massive pulmonary embolism with hemodynamic instability (shock, right heart failure) is another core indication: a large clot obstructing pulmonary circulation can be rapidly fatal, and thrombolysis dissolves it faster than anticoagulation alone allows.

Thrombolytics are also delivered locally: catheter-directed thrombolysis infuses the drug directly into a clot at a lower dose, achieving local breakdown with less bleeding risk. A common bedside use is line clearance — instilling a small amount of alteplase into a clotted catheter to dissolve the fibrin sheath and restore patency.

Contraindications

Because thrombolytics activate plasmin throughout the body, they break down protective clots too, such as at a healing surgical site. This produces a long list of contraindications built on bleeding risk. Absolute contraindications include prior intracranial hemorrhage, a known cerebral vascular lesion or malignant intracranial neoplasm, a recent ischemic stroke, active internal bleeding, suspected aortic dissection, significant recent head or facial trauma, severely uncontrolled hypertension, recent major surgery, and a known bleeding diathesis. Relative contraindications soften these themes — an older stroke, minor trauma, pregnancy, active peptic ulcer disease — and require case-by-case weighing.

The feared complication and monitoring

Intracranial hemorrhage defines the risk-benefit conversation for thrombolytics. Because the drug cannot distinguish a target clot from a fragile vessel, bleeding into the brain can convert a treatable ischemic stroke into a fatal hemorrhagic one. This is why administration triggers intensive monitoring: frequent neurologic checks (headache, decreased consciousness, weakness, pupil changes) and tight blood pressure control, since elevated pressure raises hemorrhage risk into already-injured vessels. Neuro checks and vitals run far more often than routine assessments.

Nursing considerations

Because any needle stick becomes a bleeding risk once fibrinolysis is activated, nursing care emphasizes minimizing invasive interventions: avoiding unnecessary venipunctures, deferring arterial lines and urinary catheters when possible, and applying prolonged pressure to any accessed site. Lines and IV sites are watched for oozing, and patients are observed for bleeding anywhere — gums, urine, stool, or bruising. Any sudden neurologic change is treated as hemorrhage until proven otherwise, and the infusion stops immediately if bleeding is suspected.